Abstract
Background: Immune checkpoint inhibitors (ICIs) have recently become a major strategy in treatment of non-small cell lung cancer (NSCLC), but somatic mutations involving the STK11 and KEAP1 genes may elicit resistance to anti-PD(L)1 agents. We conducted a systematic review aiming to determine if these mutations are significantly related to poorer outcomes in NSCLC patients (pts) treated with ICIs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
